15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      P15-01. Willingness to participate in actual preventive HIV vaccine phase I/IIa trial in Bangkok, Thailand

      abstract
      1 , 2 , , 3 , 3 , 1 , 1 , 3 , 1 , 1
      Retrovirology
      BioMed Central
      AIDS Vaccine 2009
      19–22 October 2009

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background Willingness to participate (WTP) in prophylactic HIV vaccine trials have been investigated amongst individuals at high risk for HIV and not in the actual HIV vaccine trial itself. We assessed the willingness and barriers to participation in an actual preventive HIV vaccine trial. Methods General population in Bangkok inquired about the HIV vaccine trial. Several questionnaires on HIV vaccine trial knowledge were completed during the recruitment process of phase I/IIa trial of DNA/Fowlpox vaccine. Self administered questionnaires on sexual HIV risk behavior, reasons and concerns to participate were completed at the end of the trial by participants and non-participants. Results From 131 participants who inquired, the median age was 34 years (IQR: 27 – 46), 73% were male and 30% had at least a bachelor's degree and 11% were screened for the trial. Only 34% completed HIV vaccine knowledge questionnaires, the median score was not significantly different between those who came to screen and those who did not (median score was 7 (IQR 6 – 8) and 6 (IQR 5 – 8) respectively; p = 0.44). Baseline characteristics and method to recruit participants were not different between two groups. Of the 43% who completed self-administered questionnaires, those who were, male gender were more willing (p = 0.038; OR = 6.29, 95% CI = 0.75–52.68) by univariate analysis. Age and education were not associated with WTP. Knowing someone infected with HIV significantly decreased WTP (p = 0.04; OR = 0.23, 95% CI = 0.05–1.01). The most common reasons volunteers declined to participate were concerns that their family would not want them to join and being not sure about the safety of the vaccine. Conclusion The low rate of actual WTP is common to HIV vaccine trials. Community education on the importance and safety of the vaccine is needed.

          Related collections

          Author and article information

          Conference
          Retrovirology
          Retrovirology
          BioMed Central
          1742-4690
          2009
          22 October 2009
          : 6
          : Suppl 3
          : P202
          Affiliations
          [1 ]Medical department, HIVNAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, Bangkok, Thailand
          [2 ]National Centre in HIV Epidemiology and Clinical Research, 376 Victoria Street, Australia
          [3 ]National Centre in HIV Epidemiology and Clinical Research, 376 Victoria Street, Australia
          Article
          1742-4690-6-S3-P202
          10.1186/1742-4690-6-S3-P202
          2767696
          d93e2ee0-cbec-4fde-a385-9ad64714a89c
          Copyright © 2009 Hemachandra et al; licensee BioMed Central Ltd.
          AIDS Vaccine 2009
          Paris, France
          19–22 October 2009
          History
          Categories
          Poster Presentation

          Microbiology & Virology
          Microbiology & Virology

          Comments

          Comment on this article